Breaking News

BMS Completes $14B Acquisition of Karuna Therapeutics

Adds KarXT, a potential first-in-class treatment for schizophrenia with potential across multiple indications.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol Myers Squibb completed its acquisition of Karuna Therapeutics, Inc. for approximately $14 billion. Karuna is now a wholly owned subsidiary of BMS.    Through this transaction, BMS has added KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of action and a differentiated efficacy and safety profile, and Karuna’s early-stage and pre-clinical pipeline. KarXT has a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024 for the treatment of schizophrenia in adu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters